Skip to content

High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis

High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis: a Crossover Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04564664
Enrollment
10
Registered
2020-09-25
Start date
2019-03-01
Completion date
2021-03-30
Last updated
2021-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis

Keywords

exertional desaturation, high-flow nasal cannula

Brief summary

Objectives: 1. To evaluate endurance time during cardiopulmonary exercise test (CPET) performance comparing standard oxygen therapy to high-flow nasal cannula (HFNC) oxygen therapy in subjects with idiopathic pulmonary fibrosis (IPF) with exertional desaturation. 2. To assess oxygenation level (peripheral and muscular) as well as dyspnea and fatigue during exercise in IPF subjects with exertional desaturation using oxygen supplementation with HFNC compared with standard oxygen supplementation. Method: multicenter crossover clinical trial. Patients with IPF presenting oxygen desaturation during the six-minute walking test (6MWT) (SpO2 mean ≤ 85%) will be included consecutively . Each subject evaluated will perform initially an incremental CPET to evaluate the patient's maximum exercise capacity. Supplemental oxygen will be applied to maintain SpO2 \>85% with a Venturi mask. Maximum exercise capacity and the appropriate final oxygen inspiratory fraction (FiO2) needed for the following tests will be determined. Posteriorly each patient will perform two constant load CPET (at 75% of the maximum workload achieved with the incremental CPET); one with standard oxygen therapy and the other one with HFNC oxygen therapy. Endurance time, dyspnea and leg fatigue and oxygen saturation (peripheral and muscular) will be recorded. Evaluation measures: Endurance time, dyspnea and leg fatigue (Borg scale), and oxygen saturation.

Interventions

DRUGOxygen

High-flow nasal cannula oxygen therapy vs. standard oxygen therapy

Sponsors

Hospitales Universitarios Virgen del Rocío
CollaboratorOTHER
Parc de Salut Mar
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Subjects with IPF diagnosis according to the 2018 international consensus guidelines * Mean SpO2 ≤ 85% during the 6MWT performed under room air conditions

Exclusion criteria

* Fibrotic interstitial lung diseases other than IPF * Chronic obstructive pulmonary disease (COPD) * Inability to perform a complete CPET due to osteo-articular or cognitive limitations * End-stage lung disease * Severe pulmonary hypertension

Design outcomes

Primary

MeasureTime frameDescription
Endurance timethrough study completion, an average of 1 weekEndurance time (s) during the constant load CPET performance with standard oxygen therapy compared to HFNC oxygen therapy

Secondary

MeasureTime frameDescription
Dyspnea and fatiguethrough study completion, an average of 1 weekDyspnea and fatigue (Borg scale) at the end of the constant load CPET with standard oxygen therapy compared to HFNC oxygen therapy
Oxygen saturationthrough study completion, an average of 1 weekPeripheral oxygen saturation (SpO2) during the constant load CPET with standard oxygen therapy compared to HFNC oxygen therapy
Muscle oxygen saturation (StO2)through study completion, an average of 1 weekMuscle oxygen saturation (StO2) during the constant load CPET with standard oxygen therapy compared to HFNC oxygen therapy

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026